NO20022264L - Farmasoytisk blanding inneholdende tolterodin, samt anvendelse derav - Google Patents

Farmasoytisk blanding inneholdende tolterodin, samt anvendelse derav

Info

Publication number
NO20022264L
NO20022264L NO20022264A NO20022264A NO20022264L NO 20022264 L NO20022264 L NO 20022264L NO 20022264 A NO20022264 A NO 20022264A NO 20022264 A NO20022264 A NO 20022264A NO 20022264 L NO20022264 L NO 20022264L
Authority
NO
Norway
Prior art keywords
tolterodine
pharmaceutical composition
composition containing
hours
active ingredient
Prior art date
Application number
NO20022264A
Other languages
English (en)
Other versions
NO20022264D0 (no
Inventor
Lisbeth Nilvebrant
Bengt Hallen
Birgitta Olsson
Jan Stroembom
Torkel Gren
Anders Ringberg
Martin Wikberg
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56290073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20022264(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/SE1999/002052 external-priority patent/WO2000027364A1/en
Priority claimed from SE0000782A external-priority patent/SE0000782D0/xx
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Publication of NO20022264L publication Critical patent/NO20022264L/no
Publication of NO20022264D0 publication Critical patent/NO20022264D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20022264A 1999-11-11 2002-05-13 Farmasöytisk blanding inneholdende tolterodin, samt anvendelse derav NO20022264D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/SE1999/002052 WO2000027364A1 (en) 1998-11-11 1999-11-11 New controlled release bead, a method of producing the same and multiple unit formulation comprising it
SE0000782A SE0000782D0 (sv) 1999-11-11 2000-03-09 Pharmaceutical formulation and its use
PCT/SE2000/002061 WO2001034139A1 (en) 1999-11-11 2000-10-24 Pharmaceutical formulation containing tolterodine and its use

Publications (2)

Publication Number Publication Date
NO20022264L true NO20022264L (no) 2002-05-13
NO20022264D0 NO20022264D0 (no) 2002-05-13

Family

ID=56290073

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022264A NO20022264D0 (no) 1999-11-11 2002-05-13 Farmasöytisk blanding inneholdende tolterodin, samt anvendelse derav

Country Status (24)

Country Link
US (1) US6630162B1 (no)
EP (1) EP1227806B1 (no)
JP (1) JP2003513918A (no)
KR (2) KR20070091374A (no)
CN (1) CN100353935C (no)
AT (1) ATE300941T1 (no)
AU (1) AU784104B2 (no)
BR (1) BR0015346A (no)
CA (1) CA2387973C (no)
CZ (1) CZ304671B6 (no)
DE (1) DE60021749T2 (no)
DK (1) DK1227806T3 (no)
EE (1) EE05191B1 (no)
ES (1) ES2245320T3 (no)
HK (1) HK1054196B (no)
HU (1) HUP0203028A3 (no)
MX (1) MXPA02004574A (no)
NO (1) NO20022264D0 (no)
NZ (1) NZ518309A (no)
PL (1) PL356166A1 (no)
PT (1) PT1227806E (no)
SI (1) SI1227806T1 (no)
SK (1) SK6412002A3 (no)
WO (1) WO2001034139A1 (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
ATE300941T1 (de) * 1999-11-11 2005-08-15 Pfizer Health Ab Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung
AU2002360717A1 (en) * 2001-12-20 2003-07-09 Pharmacia Corporation Controlled release dosage form having improved drug release properties
DE10224556A1 (de) * 2002-05-31 2004-01-08 Grünenthal GmbH 1-Dimethylamino- 3-(3-methoxy-phenyl)2-methyl-pentan-3-ol entaltendes Arzneimittel in verschiedenen Formulierungen
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
AU2003303041B2 (en) * 2002-12-13 2008-07-24 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
ES2324712T5 (es) † 2003-01-22 2012-06-08 Pfizer Health Ab Dosis reducida de tolterodina para tratar trastornos urinarios
SE0300830D0 (sv) * 2003-03-26 2003-03-26 Pharmacia Ab New formulations and use thereof
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
WO2004105735A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
WO2005105036A1 (en) * 2004-04-28 2005-11-10 Natco Pharma Limited Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
EP1629834A1 (en) * 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
CN100382794C (zh) * 2004-08-30 2008-04-23 鲁南制药集团股份有限公司 酒石酸托特罗定的分散片剂型
CN1795845B (zh) * 2004-12-23 2010-10-13 李又欣 作为毒蕈碱受体拮抗剂的3，3-二苯基丙胺衍生物注射用缓释微球制剂
CN1330297C (zh) * 2005-07-04 2007-08-08 宛六一 酒石酸托特罗定软胶囊及其制备方法
EP2015735A1 (en) * 2006-04-21 2009-01-21 Synthon B.V. Tolterodine beads
CZ2006506A3 (cs) * 2006-08-09 2007-10-03 Zentiva, A. S. Farmaceutická kompozice s obsahem tolterodinu
KR100851033B1 (ko) * 2007-02-12 2008-08-12 명문제약주식회사 엘-주석산 톨터로딘 함유 서방성 제제의 제조방법
KR20080094473A (ko) * 2007-04-20 2008-10-23 한국화학연구원 음이온성 지질나노입자 및 이의 제조방법
CL2008001970A1 (es) * 2007-07-03 2009-03-27 Synthon Bv Perla con un nucleo de celulosa microcristalina, un recubrimiento soluble en agua con un polimero vinil pirrolidina, una capa con tolterodina y un aglutinante, y una capa de liberacion controlada con un poliacrilato; proceso para prepararla; forma de dosificacion, util en trastornos urinarios como vejiga hiperactiva.
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8110226B2 (en) 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
EP2175843B1 (en) 2007-08-08 2014-10-08 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
WO2009080061A1 (en) * 2007-12-20 2009-07-02 Pharmathen S.A. Sustained-release pharmaceutical formulation containing an antimuscarinic agent and a wetting agent as well as a process for the preparation thereof
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
WO2010096820A1 (en) * 2009-02-23 2010-08-26 Eurand, Inc. Controlled release compositions comprising anti-cholinergic drugs
AU2010277207B2 (en) * 2009-07-31 2014-06-26 Sun Pharmaceutical Industries Limited Multi-layered, multiple unit pharmaceutical compositions
WO2011077239A2 (en) 2009-12-23 2011-06-30 Lupin Limited Slow release pharmaceutical compositions of iloperidone
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
EP2563123B1 (en) 2010-04-30 2018-04-25 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
US8392016B2 (en) 2010-06-25 2013-03-05 LNT PM Inc. Adaptive method for manufacturing of complicated shape parts by hot isostatic pressing of powder materials with using irreversibly deformable capsules and inserts
US8940763B2 (en) 2011-05-10 2015-01-27 Theravida, Inc. Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
AU2014332024B2 (en) 2013-10-07 2019-09-26 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
AU2015305215A1 (en) * 2014-08-22 2017-04-06 Medipath, Inc. Compositions and methods for cannabinoid coatings for use in drug delivery
KR102495757B1 (ko) 2016-01-20 2023-02-06 테라비다, 인코포레이티드 다한증을 치료하기 위한 방법 및 조성물
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1144911B (it) 1981-03-19 1986-10-29 Pharmatec Spa Composizione farmaceutica a rilascio controllato contenente ibuprofen
US5382600A (en) 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
NZ252598A (en) 1992-05-13 1997-01-29 Alza Corp Device for the transdermal administration of oxybutynin (or salts thereof) comprising a backing material, drug reservoir having a permeation enhancer and means of contact with the skin
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
JPH0710745A (ja) * 1993-06-22 1995-01-13 Tanabe Seiyaku Co Ltd 放出開始時間制御型腸デリバリー経口製剤
JP3453186B2 (ja) * 1994-04-14 2003-10-06 共和薬品工業株式会社 徐放性マイクロカプセルおよびその製造方法
SE9402422D0 (sv) 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
AU7994694A (en) 1994-10-21 1996-05-15 Leiras Oy Controlled release oral delivery system containing oxybutynin
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
AU728395B2 (en) * 1996-07-19 2001-01-11 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
CA2266070A1 (en) 1996-09-19 1998-03-26 American Home Products Corporation Method of treating urinary incontinence
JPH11193271A (ja) * 1997-10-31 1999-07-21 Ss Pharmaceut Co Ltd アリール酢酸アミド誘導体又はその塩及びこれを含有する医薬
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
SE9803871D0 (sv) * 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
PT1039882E (pt) * 1998-08-27 2011-01-03 Pfizer Health Ab Formulação terapêutica para administrar tolterodina com libertação controlada
ATE300941T1 (de) * 1999-11-11 2005-08-15 Pfizer Health Ab Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung

Also Published As

Publication number Publication date
HK1054196A1 (en) 2003-11-21
NO20022264D0 (no) 2002-05-13
DE60021749D1 (de) 2005-09-08
KR100838930B1 (ko) 2008-06-16
CN1420767A (zh) 2003-05-28
DK1227806T3 (da) 2005-10-31
US6630162B1 (en) 2003-10-07
HK1054196B (zh) 2008-08-01
EP1227806A1 (en) 2002-08-07
KR20070091374A (ko) 2007-09-10
EP1227806B1 (en) 2005-08-03
JP2003513918A (ja) 2003-04-15
PT1227806E (pt) 2005-10-31
EE05191B1 (et) 2009-08-17
ATE300941T1 (de) 2005-08-15
CZ20021617A3 (cs) 2002-11-13
AU784104B2 (en) 2006-02-02
DE60021749T2 (de) 2006-04-20
CA2387973C (en) 2009-12-22
WO2001034139A1 (en) 2001-05-17
SK6412002A3 (en) 2002-09-10
CN100353935C (zh) 2007-12-12
SI1227806T1 (sl) 2005-12-31
HUP0203028A2 (hu) 2003-02-28
CA2387973A1 (en) 2001-05-17
BR0015346A (pt) 2002-06-25
CZ304671B6 (cs) 2014-08-27
HUP0203028A3 (en) 2005-07-28
PL356166A1 (en) 2004-06-14
NZ518309A (en) 2003-05-30
AU1319201A (en) 2001-06-06
EE200200245A (et) 2003-06-16
KR20020062302A (ko) 2002-07-25
ES2245320T3 (es) 2006-01-01
MXPA02004574A (es) 2004-09-10

Similar Documents

Publication Publication Date Title
NO20022264L (no) Farmasoytisk blanding inneholdende tolterodin, samt anvendelse derav
NZ504618A (en) Controlled release therapeutic formulation for administering tolterodine maintaining a constant serum level
LU90956I2 (fr) Metvix principe actif méthylaminolevulinique sous forme d'un selde préférence l'hyhrochlorure méthylaminolevulinique
MXPA02005536A (es) Acidos aminopropilfosfinicos novedosos.
CA2126611A1 (en) Opiod Formulations Having Extended Controlled Release
MX9504034A (es) Formas de administracion medicamentosas que contienen acido tioctico, o sales solidas del acido tioctico de liberacion y biodisponibilidad mejoradas.
ATE67933T1 (de) Hydromorphon-zusammensetzung mit gesteuerter wirkstofffreisetzung.
ES8603870A1 (es) Un procedimiento para la preparacion de derivados de 2,2'-iminobisetanol.
LV12766A (lv) Composition of l-dopa esters
EP0779889A4 (en) PYRAZOLO 3,4-g] QUINOXALINE COMPOUNDS INHIBITING FCDP RECEPTOR PROTEIN TYROSINE KINASE
IL148874A0 (en) Sulfonyl amino acid derivatives, their preparation and pharmaceutical compositions containing them
MY108482A (en) Compounds.
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
TR200102087T2 (tr) Yeni morfolinbenzamid tuzları
BR0011845A (pt) Complexo farmacêutico
SE0000782D0 (sv) Pharmaceutical formulation and its use
SE9202218D0 (sv) Pharmacologically active alfa-(tertiary-aminomethyl)-benzenemethanol derivatives, pharmaceutical composition containing them, therapeutical use thereof and processes for their preparation
GEP20053512B (en) S-Methyl-Dihydro-Ziprasidone for Treatment of Psychiatric and Ocular Disorders.
WO2001000187A3 (en) Pharmaceutical composition containing sibutramine and a lipase inhibitor
DK0541726T3 (da) Vækstfaktorsammensætninger, fremstilling og anvendelse
BR9915009A (pt) Composto, composição farmacêutica, método de estimular a liberação do hormÈnio do crescimento da pituitária de um mamìfero, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
GB1420976A (en) Pharmaceutical compositions for use in the treatment of certain respiratory diseases or conditions in prematurely born children
RU97113692A (ru) Применение 3,4-дифенилхроманов для получения фармацевтической композиции для лечения или профилактики церебральных дегенеративных расстройств
EP1413302A3 (en) Substituted guanidines for the treatment of pain

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application